针对NF-κB和NLRP3的纳米聚合物可降低神经炎症,并改善随着衰老和陶病变的认知功能
Devin Wahl1,2, Sydney J Risen3,4, Shelby C Osburn1,2
1Department of Health and Exercise Science, Colorado State University, 1582 Campus Delivery, Fort Collins, CO, 80523, USA.
Journal of neuroinflammation
|July 27, 2024
概括
一种针对NF-κB和NLRP3途径的新型纳米聚合物疗法减少了老化和陶病小鼠模型中的脑炎症,并改善了老化和陶病小鼠模型中的认知功能.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 神经炎症与衰老和阿尔茨海默病中的认知衰退有关.
- NF-κB和NLRP3信号轴驱动与年龄和tau相关的神经炎症.
- 现有的NF-κB/NLRP3治疗方法存在局限性,包括系统性副作用和不良的临床转化.
研究的目的:
- 评估一种新型核酸治疗 (纳米聚合物) 尾酒,针对大脑中的NF-κB和NLRP3.
- 评估这种纳米聚合物治疗在减少神经炎症和增强老年小鼠和病小鼠模型的认知功能方面的疗效.
主要方法:
- 用一种新型NF-κB/NLRP3向纳米聚合物尾酒治疗老野生型小鼠和RTg4510病理小鼠.
- 在治疗4周后,分析了神经炎症标志物,认知行为功能,质细胞激活和转录组特征.
主要成果:
- 在两种小鼠模型中,纳米高分子治疗显著降低了大脑神经炎症性细胞因子 (cytokine) 概况.
- 认知行为功能在老年和rTg4510小鼠中都得到了改善.
- 治疗导致质细胞活化降低,质细胞相关炎症转录组减少,神经元健康转录组增加,具有积极的全身效应.
结论:
- 使用纳米聚合物准大脑中的NF-κB和NLRP3通路是一个有前途的策略.
- 这种方法有效地减少神经炎症,并在衰老和神经退行模型中改善认知功能.
- 结果支持进一步的翻译研究,用于临床应用在与年龄相关的认知衰退和阿尔茨海默病中.
相关概念视频
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456


